Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol

Wenzel, 2021, Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores, Prostate, 81, 874, 10.1002/pros.24184 Mottet N, Cornford P, van den Bergh R, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. Presented at the EAU Annual Congress Milan 2023. Knipper, 2020, Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy, Urol Oncol, 38, 184, 10.1016/j.urolonc.2019.12.014 Carlsson, 2023, Salvage radiotherapy after radical prostatectomy: functional outcomes in the LAPPRO trial after 8-year follow-up, Scand J Urol, 58, 11, 10.2340/sju.v58.7318 Attard, 2022, Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol, Lancet, 399, 447, 10.1016/S0140-6736(21)02437-5 Kumar, 2006, Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer, Cochrane Database Syst Rev, 2006, 10.1002/14651858.CD006019 Shelley, 2009, A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma, Cancer Treat Rev, 35, 9, 10.1016/j.ctrv.2008.08.002 Devos, 2021, Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer, Nat Rev Urol, 18, 739, 10.1038/s41585-021-00514-9 Eastham, 2020, Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer, J Clin Oncol, 38, 3042, 10.1200/JCO.20.00315 Rajwa, 2022, Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis, Eur Urol, 82, 82, 10.1016/j.eururo.2022.03.031 Ge, 2022, Neoadjuvant chemohormonal therapy in prostate cancer before radical prostatectomy: a systematic review and meta-analysis, Front Oncol, 12, 10.3389/fonc.2022.906370 McKay, 2021, Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials, J Urol, 205, 1689, 10.1097/JU.0000000000001632 Taplin, 2014, Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study, J Clin Oncol, 32, 3705, 10.1200/JCO.2013.53.4578 McKay, 2019, Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone, J Clin Oncol, 37, 923, 10.1200/JCO.18.01777 Montgomery, 2017, Neoadjuvant enzalutamide prior to prostatectomy, Clin Cancer Res, 23, 2169, 10.1158/1078-0432.CCR-16-1357 Lee, 2022, NEAR trial: a single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer, Prostate Cancer Prostatic Dis, 25, 741, 10.1038/s41391-022-00496-8 McKay, 2021, Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer, J Urol, 206, 80, 10.1097/JU.0000000000001702 Devos, 2023, ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer, Eur Urol, 83, 508, 10.1016/j.eururo.2022.09.009 Yanagisawa, 2023, Neoadjuvant androgen receptor signaling inhibitors before radical prostatectomy for non-metastatic advanced prostate cancer: a systematic review, J Pers Med, 13, 641, 10.3390/jpm13040641 Taplin, 2020, J Clin Oncol, 38, 10.1200/JCO.2020.38.6_suppl.TPS383 Fizazi, 2020, Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide, N Engl J Med, 383, 1040, 10.1056/NEJMoa2001342 Smith, 2022, Darolutamide and survival in metastatic, hormone-sensitive prostate cancer, N Engl J Med, 386, 1132, 10.1056/NEJMoa2119115 Maluf, 2021, A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415), Eur J Cancer, 158, 63, 10.1016/j.ejca.2021.08.032 Ohlmann, 2022, LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial, Prostate Cancer Prostatic Dis, 25, 778, 10.1038/s41391-022-00533-6 Tombal, 2023, A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532), J Clin Oncol, 41(6_suppl):160 Shore, 2022, Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial, JAMA Oncol, 8, 1128, 10.1001/jamaoncol.2022.1641 Tombal, 2014, Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study, Lancet Oncol, 15, 592, 10.1016/S1470-2045(14)70129-9 Ravi, 2022, Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis, J Urol, 208, 838, 10.1097/JU.0000000000002803 Efstathiou, 2019, Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone, Eur Urol, 76, 418, 10.1016/j.eururo.2019.05.010 Rubinstein, 2005, Design issues of randomized phase II trials and a proposal for phase II screening trials, J Clin Oncol, 23, 7199, 10.1200/JCO.2005.01.149 Lan, 1983, Discrete sequential boundaries for clinical trials, Biometrika, 70, 659, 10.2307/2336502 Devos, 2021, Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review, World J Urol, 39, 3177, 10.1007/s00345-021-03611-x Mazzone, 2022, Risk stratification of patients candidate to radical prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: development and external validation of novel risk groups, Eur Urol, 81, 193, 10.1016/j.eururo.2021.07.027 Jackson, 2022, Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer: analysis of NRG oncology/RTOG 9601, J Clin Oncol, 40, 3172, 10.1200/JCO.21.02741 Simmons, 2007, Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy, Eur Urol, 51, 1175, 10.1016/j.eururo.2007.01.015 Kang, 2018, First postprostatectomy ultrasensitive prostate-specific antigen predicts survival in patients with high-risk prostate cancer pathology, Eur Urol Oncol, 1, 378, 10.1016/j.euo.2018.07.008 Tilki, 2019, External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort, Eur Urol, 75, 896, 10.1016/j.eururo.2019.03.016 Wenzel, 2022, Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis, Prostate Cancer Prostatic Dis, 25, 139, 10.1038/s41391-021-00395-4 Morgans, 2023, Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR, J Clin Oncol, 41, 5097, 10.1200/JCO.2023.41.16_suppl.5097 Yang, 2022, Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial, Int J Urol, 29, 1322, 10.1111/iju.14994